GlassScriptPhysician profile
Bruce R Steinberg
NPI 1053431023
$3,493.14
in general payments reported to CMS, 2019-2025
22 companies · $213 in 2025
The $213 reported for 2025 was more than what a typical Addiction Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $152).
See the full distribution for Addiction Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,565 · 2020: $253 · 2021: $205 · 2022: $104 · 2023: $145 · 2024: $1,008 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,366.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $553.81 | 2021-2025 | Vraylar |
| Lundbeck LLC | $553.50 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $335.63 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $264.06 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $242.49 | 2019-2024 | Rexulti |
| Allergan, INC. | $228.65 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $199.29 | 2022-2024 | Qelbree |
| Neos Therapeutics, LP | $158.93 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $155.62 | 2023-2024 | Caplyta |
| Axsome Therapeutics, INC. | $125.00 | 2024 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $122.80 | 2024 | Austedo Xr |
| Collegium Pharmaceutical, INC. | $118.49 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $107.07 | 2019-2024 | |
| Shire North American Group INC | $57.82 | 2019 | |
| Tris Pharma INC | $53.90 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $53.72 | 2019-2020 | |
| Bausch Health US, LLC | $47.43 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $30.42 | 2019 | |
| Noven Pharmaceuticals, INC. | $28.04 | 2024 | Xelstrym |
| Sunovion Pharmaceuticals INC. | $23.30 | 2022 | |
| Avanir Pharmaceuticals, INC. | $21.43 | 2019 | |
| Janssen Scientific Affairs, LLC | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Steinberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.